Proceedings of the Ninth International Conference of Drug Regulatory Authorities (ICDRA) - Berlin, Germany 25-29 April 1999
(1999; 102 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoOpening Ceremony
Abrir esta carpeta y ver su contenidoGood regulatory practice
Abrir esta carpeta y ver su contenidoGood certification practice
Abrir esta carpeta y ver su contenidoCounterfeit drugs: challenges and solutions
Abrir esta carpeta y ver su contenidoCurrent issues in regulation and quality
Abrir esta carpeta y ver su contenidoInternational Conference on Harmonization: implementation and implications
Abrir esta carpeta y ver su contenidoDrug utilization studies
Cerrar esta carpetaInternational Conference on Harmonization and the common technical document
Ver el documentoNon-ICH country perspective: Switzerland
Ver el documentoThe ICH common technical document (CTD)
Ver el documentoSummary
Abrir esta carpeta y ver su contenidoKeynote address
Abrir esta carpeta y ver su contenidoGlobal and national efforts to reduce tobacco use
Abrir esta carpeta y ver su contenidoElectronic communication in the regulatory process
Abrir esta carpeta y ver su contenidoTransparency in monitoring the safety of medicines
Abrir esta carpeta y ver su contenidoPharmaceutical products for use in special groups
Abrir esta carpeta y ver su contenidoNeed for Bioequivalence
Abrir esta carpeta y ver su contenidoAntimicrobial resistance: battling the bugs
Abrir esta carpeta y ver su contenidoSafety issues of plasma-derived medicinal products
Abrir esta carpeta y ver su contenidoHerbal medicines
Abrir esta carpeta y ver su contenidoRegulation and access to essential drugs
Ver el documentoParticipants
Ver el documentoBack cover
 

The ICH common technical document (CTD)

Dr J. Idanpaan-Heikkila, World Health Organization

Many obstacles have been identified in the development of CTD. Although the ICH guidelines cover many subtopics there are, as yet, no complete ICH guidelines covering the totality of requirements for quality, safety and efficacy. This means that gaps must be filled by national regulations.

Moreover, ICH CTD covers only new drug substances and products, excluding the widely used, well established substances and the multisource (generic) products that make up a substantive part of the daily work of drug regulators worldwide. GMP and quality requirements for starting materials, excipients, and active pharmaceutical ingredients have proven to be difficult and complicated areas of harmonization within the CTD.

ICH stability guidelines do not cover generic products or climatic zones III and IV (hot and dry and hot and moist) that are both critical and typical for many developing and tropical countries. Although agreement may exist for safety documentation, efficacy requirements which cover a variety of diseases are difficult to harmonize.

The potential benefits of CTD can be extensive. A single format CTD could facilitate communication and exchange of information between regulators and the industry. Application made by electronic submission would be easier and industry could save in resources and time if the content of one application was the same for all ICH regulators. Finally, CTD could facilitate the evaluation process carried out by regulators but harmonization of current regulatory assessment procedures in ICH countries is also required.

As the potential benefits of CTD relate currently to tripartite countries alone, they should ideally be extended to regulators and industries worldwide. However, in order to succeed in this worldwide approach, CTD should be applicable to all countries. This requires all partners concerned to be involved in the negotiation process as early and as fully as possible. WHO is the only existing worldwide forum which could succeed in this task.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013